Fertility and sterility
-
Fertility and sterility · Feb 2021
Randomized Controlled Trial Multicenter StudyRelugolix, an oral gonadotropin-releasing hormone receptor antagonist, reduces endometriosis-associated pain in a dose-response manner: a randomized, double-blind, placebo-controlled study.
To evaluate the efficacy and safety of three dose levels of relugolix, a gonadotropin-releasing hormone receptor antagonist, compared with placebo and leuprorelin in women with endometriosis-associated pain. ⋯ NCT01458301.
-
Fertility and sterility · Sep 2020
Multicenter StudyPregnancy and neonatal outcomes 42 months after application of hyaluronic acid gel following dilation and curettage for miscarriage in women who have experienced at least one previous curettage: follow-up of a randomized controlled trial.
To study whether intrauterine application of auto-crosslinked polymers of hyaluronic acid (ACP) gel after dilation and curettage (D&C) improves reproductive outcomes. ⋯ NTR 3120.
-
Fertility and sterility · Nov 2019
Randomized Controlled Trial Multicenter StudyRelugolix, a novel oral gonadotropin-releasing hormone antagonist, in the treatment of pain symptoms associated with uterine fibroids: a randomized, placebo-controlled, phase 3 study in Japanese women.
To investigate the efficacy and safety of the oral gonadotropin-releasing hormone receptor antagonist, relugolix, in patients experiencing uterine fibroid-associated pain. ⋯ JapicCTI-163127.
-
Fertility and sterility · Sep 2019
Randomized Controlled Trial Multicenter StudyImpact of elagolix on work loss due to endometriosis-associated pain: estimates based on the results of two phase III clinical trials.
To estimate the impact of elagolix on work loss due to endometriosis-associated pain. ⋯ NCT01620528 (EM-I) and NCT01931670 (EM-II).
-
Fertility and sterility · Aug 2019
Randomized Controlled Trial Multicenter StudyImpact of elagolix treatment on fatigue experienced by women with moderate to severe pain associated with endometriosis.
To evaluate the efficacy of elagolix, an oral GnRH antagonist, for the reduction of fatigue in women with moderate or severe endometriosis-associated pain. ⋯ In women with moderate to severe endometriosis related pain, elagolix significantly reduces fatigue levels.